Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. DFTX
10. NKE

Go back to Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data

Morgan Stanley Reiterates Equalweight Rating on Pfizer (PFE) Following COVID Vaccine Update

July 21, 2020 8:42 AM EDT

Morgan Stanley analyst David Risinger reiterated an Equalweight rating and $36.00 price target on Pfizer (NYSE: PFE) following the company's COVID vaccine update. Results appear encouraging vs. MRNA and AZN, but x-trial comps are confounded.

Risinger await results from BNT162b2(full spike)... More

Mizuho 'Encouraged' by Pfizer (PFE) COVID-19 Vaccine Data

July 20, 2020 10:57 AM EDT

Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $38.00 price target on Pfizer (NYSE: PFE), citing continued positive progress on its COVID vaccine.

The analyst commented, "We are encouraged by new data from Pfizer and partner BioNTech on the progress they are... More